Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 176

1.

Nucleoside-modified mRNA encoding HSV-2 glycoproteins C, D, and E prevents clinical and subclinical genital herpes.

Awasthi S, Hook LM, Pardi N, Wang F, Myles A, Cancro MP, Cohen GH, Weissman D, Friedman HM.

Sci Immunol. 2019 Sep 20;4(39). pii: eaaw7083. doi: 10.1126/sciimmunol.aaw7083.

PMID:
31541030
2.

Research Mentoring Plan Involving North-South Collaborations.

Major TE, Koyabe B, Narasimhamurthy M, Nkomazana O, Friedman HM.

J Glob Oncol. 2019 Aug;5:1-3. doi: 10.1200/JGO.19.00176. No abstract available.

PMID:
31433710
3.

Successful application of prime and pull strategy for a therapeutic HSV vaccine.

Bernstein DI, Cardin RD, Bravo FJ, Awasthi S, Lu P, Pullum DA, Dixon DA, Iwasaki A, Friedman HM.

NPJ Vaccines. 2019 Aug 1;4:33. doi: 10.1038/s41541-019-0129-1. eCollection 2019.

4.

Antibody responses to crucial functional epitopes as a novel approach to assess immunogenicity of vaccine adjuvants.

Awasthi S, Hook LM, Swaminathan G, Cairns TM, Brooks B, Smith JS, Ditto NT, Gindy ME, Bett AJ, Espeseth AS, Cohen GH, Friedman HM.

Vaccine. 2019 Jun 27;37(29):3770-3778. doi: 10.1016/j.vaccine.2019.05.068. Epub 2019 May 29.

5.

A trivalent gC2/gD2/gE2 vaccine for herpes simplex virus generates antibody responses that block immune evasion domains on gC2 better than natural infection.

Hook LM, Awasthi S, Dubin J, Flechtner J, Long D, Friedman HM.

Vaccine. 2019 Jan 21;37(4):664-669. doi: 10.1016/j.vaccine.2018.11.076. Epub 2018 Dec 12.

PMID:
30551986
6.

Tuberculosis among individuals with community-acquired pneumonia presenting to emergency in Gaborone, Botswana.

Gersh JK, Feldman Z, Greenberger E, Chandra A, Friedman HM, Ho-Foster A, Haas MK.

J Public Health Afr. 2018 May 21;9(1):803. doi: 10.4081/jphia.2018.803. eCollection 2018 May 21.

7.

Vaccine-induced antibodies to herpes simplex virus glycoprotein D epitopes involved in virus entry and cell-to-cell spread correlate with protection against genital disease in guinea pigs.

Hook LM, Cairns TM, Awasthi S, Brooks BD, Ditto NT, Eisenberg RJ, Cohen GH, Friedman HM.

PLoS Pathog. 2018 May 23;14(5):e1007095. doi: 10.1371/journal.ppat.1007095. eCollection 2018 May.

8.

Evaluation of the effect of cellular SMS reminders on consistency of antiretroviral therapy pharmacy pickups in HIV-infected adults in Botswana: a randomized controlled trial.

Reid MJA, Steenhoff AP, Thompson J, Gabaitiri L, Cary MS, Steele K, Mayisela S, Dickinson D, Ehrenkranz P, Friedman HM, Linkin DR.

Health Psychol Behav Med. 2017;5(1):101-109. doi: 10.1080/21642850.2016.1271333. Epub 2017 Jan 9.

9.

A trivalent subunit antigen glycoprotein vaccine as immunotherapy for genital herpes in the guinea pig genital infection model.

Awasthi S, Hook LM, Shaw CE, Friedman HM.

Hum Vaccin Immunother. 2017 Dec 2;13(12):2785-2793. doi: 10.1080/21645515.2017.1323604. Epub 2017 May 8.

10.

An HSV-2 Trivalent Vaccine Is Immunogenic in Rhesus Macaques and Highly Efficacious in Guinea Pigs.

Awasthi S, Hook LM, Shaw CE, Pahar B, Stagray JA, Liu D, Veazey RS, Friedman HM.

PLoS Pathog. 2017 Jan 19;13(1):e1006141. doi: 10.1371/journal.ppat.1006141. eCollection 2017 Jan.

11.

Molecular association of herpes simplex virus type 1 glycoprotein E with membrane protein Us9.

Awasthi S, Friedman HM.

Arch Virol. 2016 Nov;161(11):3203-13. doi: 10.1007/s00705-016-3028-z. Epub 2016 Aug 27.

12.
13.

Leveraging HIV Programming to Enhance Access to Noncommunicable Disease Care in Southern Botswana.

Reid MJ, Haas MK, Sedigeng P, Ramogola-Masire D, Friedman HM, Ho-Foster A.

J Int Assoc Provid AIDS Care. 2016 Jan-Feb;15(1):7-10. doi: 10.1177/2325957415569310. Epub 2015 Feb 5.

PMID:
25656859
14.

Reducing risk and enhancing education: U.S. medical students on global health electives.

Reid MJ, Biller N, Lyon SM, Reilly JP, Merlin J, Dacso M, Friedman HM.

Am J Infect Control. 2014 Dec;42(12):1319-21. doi: 10.1016/j.ajic.2014.09.007. Epub 2014 Nov 25.

PMID:
25465263
15.

Blocking herpes simplex virus 2 glycoprotein E immune evasion as an approach to enhance efficacy of a trivalent subunit antigen vaccine for genital herpes.

Awasthi S, Huang J, Shaw C, Friedman HM.

J Virol. 2014 Aug;88(15):8421-32. doi: 10.1128/JVI.01130-14. Epub 2014 May 14.

16.

Better neutralization of herpes simplex virus type 1 (HSV-1) than HSV-2 by antibody from recipients of GlaxoSmithKline HSV-2 glycoprotein D2 subunit vaccine.

Awasthi S, Belshe RB, Friedman HM.

J Infect Dis. 2014 Aug 15;210(4):571-5. doi: 10.1093/infdis/jiu177. Epub 2014 Mar 20.

17.

Status of prophylactic and therapeutic genital herpes vaccines.

Awasthi S, Friedman HM.

Curr Opin Virol. 2014 Jun;6:6-12. doi: 10.1016/j.coviro.2014.02.006. Epub 2014 Mar 12. Review.

PMID:
24631871
18.

A paradigm shift: vaccine-induced antibodies as an immune correlate of protection against herpes simplex virus type 1 genital herpes.

Awasthi S, Friedman HM.

J Infect Dis. 2014 Mar;209(6):813-5. doi: 10.1093/infdis/jit658. Epub 2013 Nov 27. No abstract available.

PMID:
24285847
19.

Protection provided by a herpes simplex virus 2 (HSV-2) glycoprotein C and D subunit antigen vaccine against genital HSV-2 infection in HSV-1-seropositive guinea pigs.

Awasthi S, Balliet JW, Flynn JA, Lubinski JM, Shaw CE, DiStefano DJ, Cai M, Brown M, Smith JF, Kowalski R, Swoyer R, Galli J, Copeland V, Rios S, Davidson RC, Salnikova M, Kingsley S, Bryan J, Casimiro DR, Friedman HM.

J Virol. 2014 Feb;88(4):2000-10. doi: 10.1128/JVI.03163-13. Epub 2013 Nov 27.

20.

Yield of screening for TB and HIV among children failing to thrive in Botswana.

Arscott-Mills T, Ho-Foster A, Lowenstein M, Jibril H, Masunge J, Mweemba P, Nashara P, Makombe R, Chirenda J, Friedman HM, Steenhoff AP, Harari N.

J Trop Pediatr. 2014 Feb;60(1):27-32. doi: 10.1093/tropej/fmt072. Epub 2013 Aug 27.

21.

Live attenuated herpes simplex virus 2 glycoprotein E deletion mutant as a vaccine candidate defective in neuronal spread.

Awasthi S, Zumbrun EE, Si H, Wang F, Shaw CE, Cai M, Lubinski JM, Barrett SM, Balliet JW, Flynn JA, Casimiro DR, Bryan JT, Friedman HM.

J Virol. 2012 Apr;86(8):4586-98. doi: 10.1128/JVI.07203-11. Epub 2012 Feb 8.

22.

Cervical cancer prevention in HIV-infected women using the "see and treat" approach in Botswana.

Ramogola-Masire D, de Klerk R, Monare B, Ratshaa B, Friedman HM, Zetola NM.

J Acquir Immune Defic Syndr. 2012 Mar 1;59(3):308-13. doi: 10.1097/QAI.0b013e3182426227.

23.

Subtype distribution of human papillomavirus in HIV-infected women with cervical intraepithelial neoplasia stages 2 and 3 in Botswana.

Ramogola-Masire D, McGrath CM, Barnhart KT, Friedman HM, Zetola NM.

Int J Gynecol Pathol. 2011 Nov;30(6):591-6. doi: 10.1097/PGP.0b013e31821bf2a6.

24.

Immunization with a vaccine combining herpes simplex virus 2 (HSV-2) glycoprotein C (gC) and gD subunits improves the protection of dorsal root ganglia in mice and reduces the frequency of recurrent vaginal shedding of HSV-2 DNA in guinea pigs compared to immunization with gD alone.

Awasthi S, Lubinski JM, Shaw CE, Barrett SM, Cai M, Wang F, Betts M, Kingsley S, Distefano DJ, Balliet JW, Flynn JA, Casimiro DR, Bryan JT, Friedman HM.

J Virol. 2011 Oct;85(20):10472-86. doi: 10.1128/JVI.00849-11. Epub 2011 Aug 3.

25.

Subversion of innate and adaptive immunity: immune evasion from antibody and complement.

Hook LM, Friedman HM.

In: Arvin A, Campadelli-Fiume G, Mocarski E, Moore PS, Roizman B, Whitley R, Yamanishi K, editors. Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis. Cambridge: Cambridge University Press; 2007. Chapter 63.

26.

The herpes simplex virus 1 IgG fc receptor blocks antibody-mediated complement activation and antibody-dependent cellular cytotoxicity in vivo.

Lubinski JM, Lazear HM, Awasthi S, Wang F, Friedman HM.

J Virol. 2011 Apr;85(7):3239-49. doi: 10.1128/JVI.02509-10. Epub 2011 Jan 12.

28.

Herpes simplex virus type 2 glycoprotein E is required for efficient virus spread from epithelial cells to neurons and for targeting viral proteins from the neuron cell body into axons.

Wang F, Zumbrun EE, Huang J, Si H, Makaroun L, Friedman HM.

Virology. 2010 Sep 30;405(2):269-79. doi: 10.1016/j.virol.2010.06.006. Epub 2010 Jul 3.

29.

Sustainable International Partnership Building for Academic Medical Centers: Experiences with the Botswana-UPenn Partnership.

Cohn J, Friedman HM.

Virtual Mentor. 2010 Mar 1;12(3):179-83. doi: 10.1001/virtualmentor.2010.12.3.medu2-1003. No abstract available.

30.

Immunization with HSV-1 glycoprotein C prevents immune evasion from complement and enhances the efficacy of an HSV-1 glycoprotein D subunit vaccine.

Awasthi S, Lubinski JM, Friedman HM.

Vaccine. 2009 Nov 16;27(49):6845-53. doi: 10.1016/j.vaccine.2009.09.017. Epub 2009 Sep 15.

31.

Anterograde spread of herpes simplex virus type 1 requires glycoprotein E and glycoprotein I but not Us9.

McGraw HM, Awasthi S, Wojcechowskyj JA, Friedman HM.

J Virol. 2009 Sep;83(17):8315-26. doi: 10.1128/JVI.00633-09. Epub 2009 Jul 1.

32.

Herpes simplex virus type 1 infection increases the carbohydrate binding activity and the secretion of cellular galectin-3.

King RD, Lubinski JM, Friedman HM.

Arch Virol. 2009;154(4):609-18. doi: 10.1007/s00705-009-0351-7. Epub 2009 Mar 17.

PMID:
19291362
33.

Herpes simplex virus type 1 glycoprotein E mediates retrograde spread from epithelial cells to neurites.

McGraw HM, Friedman HM.

J Virol. 2009 May;83(10):4791-9. doi: 10.1128/JVI.02341-08. Epub 2009 Mar 11.

34.

A replication-competent, neuronal spread-defective, live attenuated herpes simplex virus type 1 vaccine.

Brittle EE, Wang F, Lubinski JM, Bunte RM, Friedman HM.

J Virol. 2008 Sep;82(17):8431-41. doi: 10.1128/JVI.00551-08. Epub 2008 Jun 18.

35.

Blocking antibody access to neutralizing domains on glycoproteins involved in entry as a novel mechanism of immune evasion by herpes simplex virus type 1 glycoproteins C and E.

Hook LM, Huang J, Jiang M, Hodinka R, Friedman HM.

J Virol. 2008 Jul;82(14):6935-41. doi: 10.1128/JVI.02599-07. Epub 2008 May 14.

36.

Risk factors for failure to be offered routine HIV testing among adult medical inpatients in Botswana.

Kessler JA, Ponce P, Saleshando G, Gluckman S, Friedman HM, Bisson G.

J Acquir Immune Defic Syndr. 2008 Apr 1;47(4):525-6. doi: 10.1097/QAI.0b013e31815b0d5b. No abstract available.

PMID:
18332769
37.

An HSV-1 gD mutant virus as an entry-impaired live virus vaccine.

Awasthi S, Lubinski JM, Eisenberg RJ, Cohen GH, Friedman HM.

Vaccine. 2008 Feb 26;26(9):1195-203. doi: 10.1016/j.vaccine.2007.12.032. Epub 2008 Jan 14.

38.

Thrombin enhances herpes simplex virus infection of cells involving protease-activated receptor 1.

Sutherland MR, Friedman HM, Pryzdial EL.

J Thromb Haemost. 2007 May;5(5):1055-61.

39.
40.

Herpes simplex virus type 1 glycoprotein e is required for axonal localization of capsid, tegument, and membrane glycoproteins.

Wang F, Tang W, McGraw HM, Bennett J, Enquist LW, Friedman HM.

J Virol. 2005 Nov;79(21):13362-72.

41.

Herpes simplex virus type 1-encoded glycoprotein C contributes to direct coagulation factor X-virus binding.

Livingston JR, Sutherland MR, Friedman HM, Pryzdial EL.

Biochem J. 2006 Jan 15;393(Pt 2):529-35.

42.
43.

Keratin, a dual role in herpes simplex virus pathogenesis.

Friedman HM.

J Clin Virol. 2006 Jan;35(1):103-5.

PMID:
15916917
44.

Herpes simplex virus type 1-encoded glycoprotein C enhances coagulation factor VIIa activity on the virus.

Sutherland MR, Friedman HM, Pryzdial EL.

Thromb Haemost. 2004 Nov;92(5):947-55.

PMID:
15543320
45.

Short interfering RNA-mediated inhibition of herpes simplex virus type 1 gene expression and function during infection of human keratinocytes.

Bhuyan PK, Karikò K, Capodici J, Lubinski J, Hook LM, Friedman HM, Weissman D.

J Virol. 2004 Oct;78(19):10276-81.

46.
47.

Blocking immune evasion as a novel approach for prevention and treatment of herpes simplex virus infection.

Judson KA, Lubinski JM, Jiang M, Chang Y, Eisenberg RJ, Cohen GH, Friedman HM.

J Virol. 2003 Dec;77(23):12639-45.

48.

Immune evasion by herpes simplex virus type 1, strategies for virus survival.

Friedman HM.

Trans Am Clin Climatol Assoc. 2003;114:103-12.

49.

Provider inaccuracy in assessing adherence and outcomes with newly initiated antiretroviral therapy.

Gross R, Bilker WB, Friedman HM, Coyne JC, Strom BL.

AIDS. 2002 Sep 6;16(13):1835-7.

PMID:
12218400
50.

Herpes simplex virus type 1 evades the effects of antibody and complement in vivo.

Lubinski JM, Jiang M, Hook L, Chang Y, Sarver C, Mastellos D, Lambris JD, Cohen GH, Eisenberg RJ, Friedman HM.

J Virol. 2002 Sep;76(18):9232-41.

Supplemental Content

Loading ...
Support Center